Comparative Pharmacology
Head-to-head clinical analysis: ULTRAVIST 370 versus VARIBAR THIN LIQUID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ULTRAVIST 370 versus VARIBAR THIN LIQUID.
ULTRAVIST 370 vs VARIBAR THIN LIQUID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated non-ionic contrast agent that attenuates X-rays due to its high iodine content (370 mg I/mL), enhancing vascular and tissue contrast during imaging. Does not bind to plasma proteins and has minimal pharmacological effects.
VARIBAR THIN LIQUID (barium sulfate) is a radiopaque contrast agent. Its mechanism involves coating the mucosal surface of the gastrointestinal tract, attenuating X-rays, and providing radiographic visualization of anatomical structures.
Adult: IV administration of 370 mg iodine/mL at 1-1.5 mL/kg (370-555 mg I/kg) for CT; up to 300 mL total. Rate: 1-5 mL/sec.
Oral administration: 30-100 mL of a 30% w/v barium sulfate suspension, given as a single dose for upper GI studies; adjust volume and concentration based on imaging technique and patient anatomy.
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged to up to 36 hours in severe renal impairment (CrCl <30 mL/min).
Not applicable; the compound is not absorbed and does not exhibit a systemic half-life. Gastrointestinal transit time is approximately 1-3 hours for small bowel follow-through, with colonic elimination occurring over 24-72 hours.
Renal: 95% unchanged within 24 hours via glomerular filtration; Biliary/Fecal: <5%; negligible biliary excretion.
VARIBAR THIN LIQUID (barium sulfate) is not absorbed systemically. It is eliminated entirely via the gastrointestinal tract, with >99% excreted unchanged in feces within 24-72 hours. Renal or biliary elimination is negligible (<0.01%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent